natgillin/translations-raw huggingface dataset:
Very common: may affect more than 1 in 10 people - involuntary and uncontrollable, or difficult or painful body movements
Vrlo često: mogu se javiti kod više od 1 na 10 osoba: - nehotični i nekontrolirani, ili otežani i bolni pokreti
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.
Neklinički podaci nisu ukazali na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti i kancerogenog potencijala.
What Ongentys is and what it is used for
Što je Ongentys i za što se koristi
The most common adverse reactions reported were nervous system disorders.
Najčešće zabilježene nuspojave bili su poremećaji živčanog sustava.
Note: A responder was a patient who had a reduction of at least 1 hour in absolute OFF-time (OFF-time responder)
Napomena: Responder je bolesnik koji je imao smanjenje od najmanje 1 sata u apsolutnom OFF-vremenu (responder s obzirom na OFF-vrijeme).
Therefore, their concomitant use should be considered with appropriate caution.
Stoga se njihova istodobna primjena mora razmotriti s odgovarajućim oprezom.
Patients should be monitored regularly for the development of impulse control disorders and review of treatment is recommended if such symptoms develop.
Bolesnike je potrebno redovito nadzirati zbog mogućeg razvoja poremećaja kontrole poriva i preporučuje se revidirati terapiju ako se razviju takvi simptomi.
Contents of the pack and other information What Ongentys contains
Sadržaj pakiranja i druge informacije Što Ongentys sadrži
The recommended dose is 50 mg once daily.
Preporučena doza je 50 mg jedanput na dan.
- if you are allergic to opicapone or any of the other ingredients of this medicine (listed in section
- ako ste alergični na opikapon ili neki drugi sastojak ovog lijeka (naveden u dijelu 6);
Taking Ongentys and quinidine together, i.e. at the same time, may decrease the effect of Ongentys.
Uzimanje Ongentysa i kinidina zajedno, tj. istodobno, može umanjiti učinak Ongentysa.
Take the medicine package and this leaflet with you.
Uzmite sa sobom pakiranje lijeka i ovu uputu.
Other metabolic pathways include glucuronidation, methylation and reduction.
Ostali metabolički putevi uključuju glukuronidaciju, metilaciju i redukciju.
Tell your doctor as soon as possible if you notice any of the following side effects:
Obratite se svom liječniku što je prije moguće ako primijetite bilo koju od sljedećih nuspojava:
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete ovaj lijek.
The capsules should be swallowed whole with water.
Kapsule je potrebno progutati cijele s vodom.
Swallow the capsule whole with a glass of water.
Kapsule progutajte cijele s čašom vode.
Although there is no evidence that either the efficacy or safety of opicapone would be affected by use of controlled-release levodopa preparations, the experience with such preparations is limited.
Iako nema dokaza da bi na učinkovitost i sigurnost opikapona mogla djelovati primjena pripravaka levodope s kontroliranim oslobađanjem, iskustvo s primjenom tih pripravaka je ograničeno.
Contact your doctor straight away if you experience any side effects at the start of treatment.
Odmah se obratite svom liječniku ako osjetite bilo koju nuspojavu na početku liječenja.
Parkinson's disease is a progressive disease of the nervous system that causes shaking and affects your movement.
Parkinsonova bolest je napredujuća bolest živčanog sustava koja uzrokuje tresenje i utječe na Vaše kretnje.
Hence, it is often necessary to adjust levodopa dosage within the first days to first weeks after initiating the treatment with opicapone (see section 4.4).
Stoga je često potrebno prilagoditi doziranje levodope tijekom prvih dana ili prvih tjedana nakon započinjanja liječenja opikaponom (vidjeti dio 4.4).
These behaviours are called ‘impulse control disorders' and can include: addictive gambling, an abnormally high sex drive or an increased preoccupation with sexual thoughts or feelings.
Takvo ponašanje naziva se „poremećaj kontrole poriva” i može uključivati: ovisničko kockanje, neuobičajeno jak spolni nagon ili pojačanu zaokupljenost seksualnim mislima ili osjećajima.
The SCOMT activity inhibition was significantly increased in elderly subjects.
Inhibicija aktivnosti S-COMT bila je značajno povećana u starijih ispitanika.
Dyskinesia was the most frequently reported treatment-emergent adverse reaction (17.7%).
Diskinezija je bila najčešća prijavljena nuspojava nastala tijekom primjene lijeka (17,7%).
Ask your doctor or pharmacist if you can take your antidepressant together with Ongentys.
Upitajte svog liječnika ili ljekarnika smijete li uzimati Vaš antidepresiv i Ongentys.
Do not use this medicine after the expiry date which is stated on the bottle/blister/carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na boci/blisteru/kutiji iza oznake EXP.
Difference to placebo p-value (95% CI)
Razlika u odnosu na placebo p-vrijednost (95% CI)
Talk to your doctor or pharmacist if you or your family/carer notices you are developing urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm you or others.
Obratite se svom liječniku ili ljekarniku ako ste Vi ili netko od Vaše obitelji/njegovatelja primijetili da ste razvili poriv ili jaku potrebu da se ponašate na način koji za Vas nije uobičajen ili se ne možete oduprijeti porivu, nagonu ili iskušenju da se upustite u neke radnje koje mogu naštetiti Vama osobno ili drugima.
What Ongentys looks like and contents of the pack
Kako Ongentys izgleda i sadržaj pakiranja
The remainder of the radioactivity was excreted in urine (mean 12.8%) and via expired air (mean 15.9%).
Preostali dio radioaktivnosti izlučio se mokraćom (srednja vrijednost 12,8%) i izdahnutim zrakom (srednja vrijednost 15,9%).
The majority of patients treated in both pivotal studies were treated with immediate-release levodopa/DDCI.
Većina bolesnika liječenih u oba ključna ispitivanja bila je liječena formulacijom s trenutnim oslobađanjem levodope/DDCI.
The patient should not take an extra dose to make up for the missed dose.
Bolesnik ne smije uzeti dodatnu dozu kako bi nadoknadio propuštenu.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Ongentys.
Bolesnici s rijetkim nasljednim problemima intolerancije na galaktozu, deficitom Lapp-laktaze ili malapsorpcijom glukoze-galaktoze, ne smiju uzimati Ongentys.
Pharmacotherapeutic group: Anti-parkinson drugs, other dopaminergic agents, ATC code: [not yet assigned]
Farmakoterapijska skupina: Antiparkinsonici, ostali dopaminergici, ATK oznaka: [nije još dodijeljena]
It increases the effects of levodopa and helps to relieve the symptoms of Parkinson's disease and movement problems.
On pojačava učinak levodope i pomaže ublažiti simptome Parkinsonove bolesti i teškoće s pokretima.
All reductions in activity essentially occurred at the highest concentration of opicapone (10 mcg/mL).
Sva smanjenja aktivnosti u biti su se događala pri najvišoj koncentraciji opikapona (10 µg/ml).
Thus, particular consideration should be given to cases where quinidine needs to be administered together with opicapone as their co-administration should be avoided.
Stoga je potreban poseban oprez u slučajevima kada se kinidin mora primjenjivati zajedno s opikaponom, jer se njihova istodobna primjena mora izbjegavati.
Side effects caused by Ongentys are usually mild to moderate and occur mostly within the first weeks of treatment.
Nuspojave uzrokovane Ongentysom obično su blage do umjerene i javljaju se većinom unutar prvih tjedana liječenja.
Symptomatic and supportive treatment should be administered as appropriate.
Potrebno je provesti simptomatsko i potporno liječenje ako se to smatra prikladnim.
Dry eye
- suhe oči
In patients taking levodopa and a peripheral DDCI, such as carbidopa or benserazide, opicapone increases levodopa plasma levels thereby improving the clinical response to levodopa.
U bolesnika koji uzimaju levodopu i periferni DDCI, poput karbidope ili benzerazida, opikapon povisuje razinu levodope u plazmi i tako poboljšava klinički odgovor na levodopu.
Opicapone reduced CYP2C9 activity through competitive / mixed type mode of inhibition.
Opikapon je smanjio aktivnost CYP2C9 kompetitivnim/miješanim modusom inhibicije.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING BOX (BLISTER OPA/Al/PVC//Al)
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA (BLISTER OPA/Al/PVC//Al)
Combination of opicapone and MAO inhibitors could result in inhibition of the majority of the pathways responsible for the metabolism of catecholamines.
Kombinacija opikapona i inhibitora MAO može imati za posljedicu inhibiciju većine metaboličkih puteva odgovornih za metabolizam katekolamina.
What you need to know before you take Ongentys 3.
Što morate znati prije nego počnete uzimati Ongentys
Take Ongentys at least one hour before or after taking your levodopa medicine.
Uzmite Ongentys najmanje jedan sat prije ili nakon što uzmete lijek koji sadrži levodopu.
However, as opicapone is to be used as adjunctive levodopa-therapy, dose adjustments may be considered based on a potentially enhanced levodopa dopaminergic response and associated tolerability.
Međutim, budući da je opikapon predviđen kao dodatak terapiji levodopom, može se razmotriti prilagođavanje doze na temelju mogućeg pojačanog dopaminergičkog odgovora na levodopu i s time povezane podnošljivosti.
There were 60 patients in the combined Phase 3 studies who were predominantly using controlled-release levodopa (i.e. >50% of their levodopa/DDCI formulations), 48 of whom were treated solely with controlled-release formulations of levodopa.
Bilo je 60 bolesnika iz kombinirane faze 3 ispitivanja koji su pretežno koristili levodopu s kontroliranim oslobađanjem (tj. >50% njihovih formulacija levodope/DDCI), 48 ih je bilo liječeno samo formulacijama levodope s kontroliranim otpuštanjem.
Other metabolites were not found in quantifiable concentrations in the majority of plasma samples collected during a clinical mass balance study.
Drugi metaboliti nisu pronađeni u mjerljivim koncentaracijama u većini uzoraka plazme prikupljenih tijekom kliničkog ispitivanja masene bilance.
In the presence of a DOPA decarboxylase inhibitor (DDCI), COMT becomes the major metabolising enzyme for levodopa, catalysing its conversion to 3-O-methyldopa (3-OMD) in the brain and periphery.
U prisutnosti inhibitora DOPA-dekarboksilaze (DDCI), COMT postaje glavni enzim koji metabolizira levodopu, katalizirajući njezinu konverziju u 3-O-metildopu (3-OMD) u mozgu i na periferiji.
Frequency categories are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
(≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
If you forget to take one dose, you should continue the treatment and take the next dose as scheduled.
Ako ste zaboravili uzeti jednu dozu lijeka, trebate nastaviti s liječenjem tako što ćete sljedeću dozu uzeti prema uobičajenom rasporedu.
The reduced metabolite of opicapone (found to be active in non-clinical studies) is a minor metabolite in human plasma, and represented less than 10% of total systemic exposure to opicapone.
Metabolit nastao redukcijom opikapona (za kojeg je utvrđeno da je aktivni metabolit u nekliničkim ispitivanjima) sporedni je metabolit u ljudskoj plazmi i predstavlja manje od 10% ukupne sistemske izloženosti opikaponu.
Ongentys should be taken once-daily at bedtime at least one hour before or after levodopa combinations.
Ongentys se treba uzimati jedanput na dan prije spavanja i najmanje jedan sat prije ili nakon uzimanja kombinacije koja sadrži levodopu.
However, clinical interaction studies conducted with warfarin showed no effect of opicapone on the pharmacodynamics of warfarin, a substrate of CYP2C9.
Međutim, klinička ispitivanja interakcije provedena s varfarinom nisu pokazala učinak opikapona na farmakodinamiku varfarina, supstrata za CYP2C9.
CI = confidence interval; N = total number of patients; n = number of patients with available information; NA = not applicable; OPC = opicapone
CI = interval pouzdanosti; N = ukupni broj bolesnika; n = broj bolesnika s dostupnim podacima; NP = nije primjenjivo; OPC = opikapon
Effect of transporters on opicapone
Učinak transportera na opikapon
If you stop taking Ongentys
Ako prestanete uzimati Ongentys
The binding of 14C-opicapone to plasma proteins was unaffected by the presence of warfarin, diazepam, digoxin and tolbutamide, and the binding of 14C-warfarin, 2-14C-diazepam, 3H-digoxin and 14C-tolbutamide was unaffected by the presence of opicapone and opicapone sulphate, the major human metabolite.
Na vezivanje 14Copikapona za proteine plazme nije utjecala prisutnost varfarina, diazepama, digoksina i tolbutamida, a na vezivanje 14C-varfarina, 2-14C-diazepama, 3H-digoksina i 14C-tolbutamida nije utjecala prisutnost opikapona i opikaponsulfata, glavnog metabolita u ljudi.
A study conducted in healthy volunteers showed that when a single dose of 50 mg opicapone was coadministered (within 1 hour) with a single dose of quinidine (600 mg), systemic exposure of opicapone decreased by 37% (AUC0-tlast).
Ispitivanje provedeno na zdravim dobrovoljcima pokazalo je da, kada se jednokratna doza od 50 mg opikapona istodobno primjenjivala (unutar jednog sata) s jednokratnom dozom kinidina (600 mg), sistemska izloženost opikaponu smanjila se za 37 % (AUC0-tlast).
As Ongentys will be used with other levodopa medicines, please also read the package leaflets of these medicines carefully.
Budući da ćete Ongentys uzimati s drugim lijekovima koji sadrže levodopu, molimo da pažljivo pročitate uputu o lijeku za te lijekove.
If you take more Ongentys than you should, tell your doctor or pharmacist, or go to a hospital immediately.
Ako uzmete više Ongentysa nego što ste trebali, odmah se obratite svom liječniku ili ljekarniku ili otiđite u bolnicu.
Since the risk to the baby/infant cannot be excluded, you should stop breast-feeding during treatment with Ongentys.
Budući da se rizik za novorođenče/dojenče ne može isključiti, za vrijeme liječenja Ongentysom trebate prekinuti s dojenjem.
For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.
U bolesnika kod kojih se javila progresivna anoreksija, astenija i gubitak tjelesne težine u relativno kratkom vremenu potrebno je razmotriti opću provjeru zdravstvenog stanja uključujući i provjeru funkcije jetre.
If unacceptable dopaminergic adverse events were seen, the levodopa dose was to be adjusted.
Ako su primijećeni neprihvatljivi dopaminergički štetni događaji, bilo je potrebno prilagoditi dozu levodope.
The European Medicines Agency has waived the obligation to submit the results of studies with opicapone in all subsets of the paediatric population with Parkinson's disease and motor fluctuations (see section 4.2 for information on paediatric use).
Europska agencija za lijekove je izuzela obvezu podnošenja rezultata ispitivanja opikapona u svim podskupinama pedijatrijske populacije s Parkinsonovom bolesti i motoričkim fluktuacijama (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
In both studies, 783 patients were treated with 25 mg or 50 mg of opicapone or placebo.
U oba ispitivanja 783 bolesnika liječeno je opikaponom u dozi od 25 mg ili 50 mg ili placebo.
a. ON-time without troublesome dyskinesias=ON-time with non-troublesome dyskinesias + ON-time without dyskinesias
ON-vrijeme bez problematičnih diskinezija=ON-vrijeme s neproblematičnim diskinezijama + ON-vrijeme bez diskinezija
In the OL studies, all patients began at a dose of 25 mg opicapone for the first week (7 days), regardless of their prior treatment in the double-blind period.
U otvorenim ispitivanjima svi bolesnici započeli su s uzimanjem doze od 25 mg opikapona u prvom tjednu ispitivanja (7 dana), neovisno o njihovom ranijem liječenju tijekom razdoblja dvostruko slijepog ispitivanja.
Hence, the precautions valid for levodopa treatment should also be taken into account for Ongentys.
Stoga je potrebno mjere opreza koje vrijede za levodopu uzeti u obzir i za Ongentys.
If you stop taking Ongentys your doctor may need to adjust the dose of other medicines that you are taking to treat Parkinson's disease.
Ako prestanete uzimati Ongentys, možda će Vaš liječnik morati prilagoditi dozu ostalih lijekova koje uzimate za liječenje Parkinsonove bolesti.
Opicapone enhances the effects of levodopa.
Opikapon pojačava učinke levodope.
To reduce levodopa-related dopaminergic adverse reactions (e.g. dyskinesia, hallucinations, nausea, vomiting and orthostatic hypotension), it is often necessary to adjust the daily dose of levodopa by extending the dosing intervals and/or reducing the amount of levodopa per dose within the first days to first weeks after initiating treatment with Ongentys, according to the clinical condition of the patient (see section 4.2).
Da bi se smanjile dopaminergičke nuspojave povezane s levodopom (npr. diskinezija, halucinacije, mučnina, povraćanje i ortostatska hipotenzija), često je potrebno prilagoditi dnevnu dozu levodope produžujući intervale između doza i/ili smanjujući količinu levodope po dozi unutar prvih dana ili tjedana nakon započinjanja liječenja Ongentysom, već prema kliničkom stanju bolesnika (vidjeti dio 4.2).
For other adverse events, the levodopa and/or opicapone dose could be adjusted.
Za kontrolu ostalih štetnih događaja doza levodope i/ili opikapona mogla se je prilagoditi.
In vitro studies over the opicapone concentration range 0.3 to 30 mcg/mL showed that binding of 14C-opicapone to human plasma proteins is high (99.9%) and concentration-independent.
In vitro ispitivanja s rasponom koncentracije opikapona od 0,3 do 30 µg/ml pokazala su da je vezivanje 14Copikapona za proteine ljudske plazme visoko (99,9%) i neovisno o koncentraciji.
Ongentys is not recommended during pregnancy and in women of childbearing potential not using contraception.
Ne preporučuje se koristiti Ongentys tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.
Ako vam je liječnik rekao da ne podnosite neke vrste šećera, obratite mu se prije nego uzmete ovaj lijek.
Some side effects may be caused by the increased effects of using Ongentys together with levodopa.
Neke nuspojave mogu biti uzrokovane pojačanim učincima primjene Ongentysa zajedno s levodopom.
The efficacy and safety of opicapone has been demonstrated in two Phase 3 double-blind, placebo and active (Study 1 only) controlled studies in 1,027 randomized adult patients with Parkinson's disease treated with levodopa/DDCI (alone or in combination with other antiparkinsonian drugs) and end-ofdose motor fluctuations for up to 15 weeks.
Djelotvornost i sigurnost opikapona pokazana je u dva dvostruko slijepa, placebom i aktivno (samo Ispitivanje 1) kontrolirana ispitivanja faze 3 u 1027 randomiziranih odraslih bolesnika s Parkinsonovom bolešću liječenih kombinacijom levodopa/DDCI (samom ili u kombinaciji s drugim antiparkinsonicima) i motoričkim fluktuacijama pri kraju doze sve do 15 tjedana.
Caution must be exercised in patients ≥ 85 years of age as there is limited experience in this age group.
≥ 85 godina, jer su iskustva s primjenom u populaciji te starosne dobi ograničena.
If one dose is missed, the next dose should be taken as scheduled.
Ako se doza propusti, sljedeću dozu potrebno je uzeti prema uobičajenom rasporedu.
If Ongentys is discontinued it is necessary to adjust the dosing of the other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the symptoms.
Prekine li se uzimanje Ongentysa potrebno je prilagoditi doziranje ostalih lijekova za liječenje Parkinsonove bolesti, posebice levodope, kako bi se postigla zadovoljavajuća kontrola simptoma.
Fax: +351 22 986 61 90 e-mail: info@bial.com
Faks: +351 22 986 61 90 e-mail: info@bial.com
Opicapone is a peripheral, selective and reversible catechol-O-methyltransferase (COMT) inhibitor endowed with a high binding affinity (sub-picomolar) that translates into a slow complex dissociation rate constant and a long duration of action (>24 hours) in vivo.
Opikapon je periferni, selektivni i reverzibilni inhibitor katekol-O-metiltransferaze (COMT) karakteriziran visokim afinitetom vezivanja (subpikomolarno), što in vivo znači nisku konstantu brzine disocijacije kompleksa i dugo trajanje djelovanja (> 24 h).
There is no relevant use of Ongentys in the paediatric population with Parkinson's disease and motor fluctuations.
Nema relevantne primjene Ongentysa u pedijatrijskoj populaciji s Parkinsonovom bolešću i motoričkim fluktuacijama.
In rats, opicapone did not affect male and female fertility or prenatal development at exposure levels 22 times the therapeutic exposure in humans.
U štakora opikapon nije imao učinka na plodnost mužjaka i ženki i na prenatalni razvoj pri 22 puta većoj izloženosti od one terapijske u ljudi.
In in vitro studies in human hepatic microsomes, minor inhibition of CYP1A2 and CYP2B6 was observed.
U in vitro ispitivanjima na mikrosomima ljudske jetre primijećena je manja inhibicija CYP1A2 i CYP2B6.
If you forget to take Ongentys
Ako ste zaboravili uzeti Ongentys
OPA/Al/PVC//Al blisters containing 10 or 30 capsules.
Blisteri OPA/Al/PVC//Al koji sadrže 10 ili 30 kapsula.
In pregnant rabbits, opicapone was less well tolerated resulting in maximum systemic exposure levels around or below the therapeutic range.
U skotnih ženki kunića opikapon je bio manje podnošljiv rezultirajući s maksimalnim razinama sistemske izloženosti približne ili ispod terapijskog raspona.
In urine, the primary metabolite was the glucuronide metabolite of opicapone, while parent drug and other metabolites were generally below the limit of quantification.
U mokraći je primarni metabolit bio glukuronid opikapona, dok su nepromijenjeni lijek i ostali metaboliti općenito bili ispod granica mjerljivosti.
It is not known if Ongentys passes into breast milk in humans.
Nije poznato prelazi li Ongentys u majčino mlijeko u ljudi.
CYP2C8 and OATP1B1 substrates
Supstrati za CYP2C8 i OATP1B1
Table 2 - Change in absolute OFF-time and ON-time (minutes) from baseline to endpoint Treatment
Tablica 2 - Promjena u apsolutnom OFF- i ON-vremenu (u minutama) od početne vrijednosti do mjerne točke ishoda
Each hard capsule contains 171.9 mg of lactose (as monohydrate).
Jedna tvrda kapsula sadrži 171,9 mg laktoze (u obliku hidrata).
There is no experience taking Ongentys and safinamide together.
Nema iskustava s istodobnim uzimanjem Ongentysa i safinamida.
Monoamino oxidase (MAO) inhibitors
Inhibitori monoaminooksidaze (MAO)
The recommended dose of opicapone is 50 mg.
Preporučena doza opikapona je 50 mg.
Doses of other medicines to treat Parkinson's disease
Doze ostalih lijekova za liječenje Parkinsonove bolesti
Taking Ongentys with these medicines may increase the risk of side effects.
Uzimanje Ongentysa s tim lijekovima može povećati rizik od nuspojava.
There are no or limited amount of data from the use of opicapone in pregnant women.
Nema podataka ili su podaci o primjeni opikapona u trudnica ograničeni.
Phaeochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.
Feokromocitom, paragangliom ili druge neoplazme koje izlučuju kateholamine.